ELEXACAFTOR + TEZACAFTOR + IVACAFTOR

Information current as at: 1 June 2026

The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Trikafta®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Vertex Pharmaceuticals (Australia) Pty Ltd
Condition/indication:
(therapeutic use)
  • Cystic fibrosis
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
New listing (Matters outstanding)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for::
July 2021 PBAC meeting
Opportunity for consumer comment:
Has not yet commenced
PBAC meeting:
Held on 07/07/2021
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Awaiting lodgement from pharmaceutical company
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – July 2021
Case ID
a437
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19